Clinical Trials Browser

Urinary Bladder Neoplasms, Bone Neoplasms, Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Glioblastoma, Hodgkin Disease, Kidney Neoplasms, Leukemia, Lung Neoplasms, Lymphoma, Lymphoma, Non-Hodgkin, Melanoma, Multiple Myeloma, Myelodysplastic Syndromes, Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Osteosarcoma, Skin Neoplasms, Testicular Neoplasms, Thyroid Neoplasms, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Small Cell Lung Carcinoma

NCT02603003 2019-09-20

CTC-TCM-FZ

Phase 1 Completed

218 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplastic Cells, Circulating

NCT02066870 2015-03-13

Icotinib and Arsenic Trioxide in Treating Non-small-cell Lung Cancer Patients With Resistance to EGFR-TKI

Phase 1 Unknown

9 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

Clinical Trials

Atezolizumab and Varlilumab in Combination With Radiation Therapy for NSCLC

SIM0610-101

A Study of APG-1252 Plus Osimertinib(AZD9291) in EGFR TKI Resistant NSCLC Patients

Study of Paclitaxel Micelles for Injection in Chinese Patients With Advanced Solid Tumors.

Phase I Clinical Study of SHR-1316 (SC) Combined With Carboplatin and Etoposide as First-line Treatment for Extensive Stage Small Cell Lung Cancer

A Study of SYS6040 for Injection in Patients With Advanced Solid Tumors

To Evaluate the Tolerability and Pharmacokinetics of TQB2101 for Injection in Patients With Advanced Malignant Tumors

APG-1252 in Patients With SCLC or Advanced Solid Tumors

Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies

CTC-TCM-FZ

Icotinib and Arsenic Trioxide in Treating Non-small-cell Lung Cancer Patients With Resistance to EGFR-TKI